While the possibility of extending patients' lives through targeted and personalized cancer therapies is a reality, still not every patient has access to them. Complicated reimbursement procedures and drug programs mean that patients not only face a disease like cancer, but also struggle with the challenges posed by the system.
One of the changes most anticipated by oncology patients was to be brought about by a new healthcare benefit proposed by the Polish Cancer Society - "Comprehensive genomic profiling (CGP) testing performed by high-throughput next-generation sequencing (NGS) for molecular diagnosis of patients with malignant tumors," which received a positive recommendation from the President of AOTMiT in October 2023.
- There can be no modern treatment without proper diagnostics. If we want oncology patients to be able to benefit from innovative targeted therapies to the optimum extent, we urgently need the decision of the Ministry of Health and changes in the reimbursement of molecular tests," argues Dorota Korycinska, president of the Board of Directors of the National Federation of Oncology and the Association of Neurofibromatosis Poland.
- Modern diagnostic solutions such as molecular testing, based on comprehensive genomic profiling, make it possible to determine up to several hundred mutations simultaneously...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
